Neuroophthalmic involvement may occur in people infected with primary human immunodeficiency virus (HIV) due to the infection itself, opportunistic infections, malignancy or due to vascular causes. However, treatment-related optic neuropathy may be considered in patients receiving Antiretroviral therapy (ART), without an identified etiological cause, despite all examinations. In this case report, a near-complete recovery was observed in vision loss of a patient, whose 4-month treatment regimen of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/FTC/TAF) was replaced with a combination of tenofovir disoproxil + emtricitabine and lopinavir+ritonavir due to the development of optic neuritis. Recognition of the present symptoms rapidly and the implementation of the necessary change is extremely important for preventing permanent damage in these patients.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895810PMC
http://dx.doi.org/10.29399/npa.26137DOI Listing

Publication Analysis

Top Keywords

optic neuritis
8
elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
8
case report
8
neuritis elvitegravir/cobicistat/emtricitabine/tenofovir
4
alafenamide case
4
report neuroophthalmic
4
neuroophthalmic involvement
4
involvement occur
4
occur people
4
people infected
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!